Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Study of an Autologous Recombinant Idiotypic Vaccine Manufactured by magnICON® Technology for the Treatment of Patients With Relapsed or Transformed Follicular Lymphoma

NCT01022255 is registered in ClinicalTrials.gov with Icon Genetics GmbH as lead sponsor.

NCT NCT01022255
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01022255 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Study of an Autologous Recombinant Idiotypic Vaccine Manufactured by magnICON® Technology for the Treatment of Patients With Relapsed or Transformed Follicular Lymphoma
Lead sponsor
Icon Genetics GmbH
Phase
Phase 1
Overall status
Completed
Start date
January 31, 2010
Completion date
October 31, 2013
Enrollment
28 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

lymphoma, follicular